





PHARMACEUTICAL 2023

Vistagen Therapeutics Inc.
Rank 155 of 446



The relative strengths and weaknesses of Vistagen Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vistagen Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 88% points. The greatest weakness of Vistagen Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 150%, being 107% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	70,998
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,765
Liabilities, Non-Current	4,163
Other Assets	3,231
Other Compr. Net Income	0
Other Expenses	3.4
Other Liabilities	0
Other Net Income	20
Other Revenues	1,109
Property and Equipment	414
Research and Development	35,408
Selling, General and Administrative Expense	13,480

Output Variable	Value in 1000 USD
Assets	74,643
Liabilities	9,928
Expenses	48,891
Revenues	1,109
Stockholders Equity	64,715
Net Income	-47,762
Comprehensive Net Income	-47,762
Economic Capital Ratio	150%